| Literature DB >> 35051200 |
Ensiyeh Taheri1,2, Mohammad Mehdi Amin1,2, Seyede Shahrbanoo Daniali3, Ibrahim Abdollahpour3, Ali Fatehizadeh1,2, Roya Kelishadi3.
Abstract
Since chlorpyrifos (CPF), a major organophosphorus pesticide, is widely used for agricultural and domestic purposes, thus, humans may be exposed to these toxic compounds through multiple sources. In recent years, significant concerns have been raised regarding the deleterious effects of exposure to CPF on human health, especially growing fetus. Therefore, in this study, we aimed to evaluate the health risks of exposure to CPF among pregnant women living in Isfahan province, Iran, using deterministic and probabilistic approaches. The urinary concentration of 3, 5, 6-trichloro-2-pyridinol (TCP), the most common metabolite of CPF, was measured as the biomarker of current exposure to CPF. For this purpose, spot urine samples were taken from 110 pregnant women and the urinary concentrations of TCP were quantified. The estimated daily intake and hazard quotient (HQ) for CPF exposure were measured according to the reference values set by World Health Organization (WHO) and United States Environmental Protection Agency (US EPA) for acute and chronic exposure to CPF. Based on the results, TCP was detected in more than 70% of samples (3.8 ± 2.72 μg/L). The estimated daily intake for some participants was found to be higher than the suggested reference dose by USEPA for chronic exposure to CPF. Furthermore, the HQ>1 was obtained for 20% of the study population in Monte-Carlo analysis using USEPA chronic reference dose, indicating that chronic toxic effects are expected at least for a part of the target population. Based on the findings, proper measures should be taken to reduce the exposure of Iranian pregnant women to CPF and resultant health risks.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35051200 PMCID: PMC8775211 DOI: 10.1371/journal.pone.0262127
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Distributions of parameters used in the risk assessment model generated with MCS.
| Parameters | Unit | Distribution | Pregnant Women | Ref. |
|---|---|---|---|---|
| EDI | μg/kg/day | - | Calculated by Eq ( | [ |
| HQ | - | - | Calculated by Eq ( | [ |
| CU | μg/L | Normal | 3.8 (2.72) | Present study |
| V24h | L/day | Normal | 1.14 (0.48) | [ |
| FUE | - | - | 70% | [ |
| ADI | μg/kg/day | Fixed value | CRfDWHO | [ |
| MWP | (g/mol) | Fixed value | 350.6 | [ |
| MWT | (g/mol) | Fixed value | 198.4 | [ |
| BW | Kg | Normal | 65.06 (13. 3) | Present study |
* Chronic reference dose by WHO (CRfDWHO) and USEPA (CRfDUSEPA), Acute reference dose by WHO (ARfDWHO), and USEPA (ARfDUSEPA).
Fig 1Calculated EDI for TCP considering the targeted population groups.
Estimated Daily Intake of the CPF and Hazard quotient values of chlorpyrifos exposure levels in pregnant women (n = 80).
| Simulation approach | 50% | 95% | Mean (STD) | |
| EDI (μg/kg/day) | 0.146 | 0.392 | 0.174 (0.127) | |
| Deterministic approach | HQ (CRfDWHO: 10) | 0.015 | 0.039 | 0.017 |
| HQ (ARfDWHO:100) | 0.001 | 0.004 | 0.002 | |
| HQ (CRfDUSEPA:0.3) | 0.486 |
| 0.581 | |
| HQ (ARfDUSEPA:5) | 0.029 | 0.078 | 0.035 | |
| Probabilistic approach | HQ (CRfDWHO: 10) | 0.01 | 0.05 | 0.02 (0.02) |
| HQ (ARfDWHO:100) | 0.00 | 0.01 | 0.00 (0.00) | |
| HQ (CRfDUSEPA:0.3) | 0.44 |
| 0.58 (0.54) | |
| HQ (ARfDUSEPA:5) | 0.03 | 0.11 | 0.03 (0.03) |
* HQ values > 1 have been bolded.
Fig 2Cumulative distribution of the HQ of CPF using the guideline values suggested by A: Chronic Reference Dose (CRfDWHO), B: Acute Reference Dose (ARfDWHO), C: Chronic Reference Dose (CRfDUSEPA), D: Acute Reference Dose (ARfDUSEPA) (The result of Crystal Ball, HQ defined as a forecast, the trial number was 10,000).
Fig 3Sensitivity analysis of noncarcinogenic risk for pregnant women (the result of Crystal Ball, the trial number was 10,000).